#### OFFICE OF GRADUATE MEDICAL EDUCATION



# **Vendor Policy**

GMEC approved April 18, 2024

## Vendor (IV.L)

**ACGME Institutional Requirements** Vendor (IV.L): The Sponsoring Institution must maintain a policy that addresses interactions between vendor representatives/corporations and residents/fellows and each of its ACGME-accredited programs. (Core)

# **Background:**

This Policy applies to all Residents in ACGME- accredited Programs sponsored by UMKC School of Medicine.

# **Purpose:**

To avoid or minimize conflicts of interest with Industry representatives and to support the mission and values of the School of Medicine.

#### **Definition:**

Industry- pharmaceutical companies, manufacturers of medical devices, and biotechnology companies.

### **Procedures:**

- 1. It is unethical for a Resident to accept gifts or support in any form from an Industry representative that results in prescription of a particular drug or product or delivery of particular clinical action.
- 2. All Programs and UMKC SOM sponsored events require full and appropriate disclosure of Industry sponsorship and financial interests.
- Full disclosure of Industry research interests is published in accordance with policies of institutional review boards and the recommendations of the AAMC Tack Force on Financial Conflicts of Interest in Research.
- 4. Programs and UMKC SOM shall determine which contracts between Residents and Industries or Industry representatives may be suitable, and when involvement by Industry representatives or promotion of an Industry product is inappropriate.
- 5. Residents and Programs shall not be identified by any Industry funding sources.
- 6. Residents shall not receive preferential treatment in the learning or working environment based upon sources of Industry funding for their positions.
- 7. Residents shall be taught:
  - a. how promotional activities can influence judgment in prescribing decisions and research activities;
  - b. how to manage encounters with Industry representatives;
  - c. how to apply appropriate considerations of cost-benefit analysis as a component of prescribing practices; and

# OFFICE OF GRADUATE MEDICAL EDUCATION



d. how to handle patient requests for drugs, particularly with regard to direct-to-consumer advertising of the drugs. Violations of this Policy by a Resident shall be deemed to reflect professionalism issues that shall be handled by the applicable Clinical Competency Committee (CCC).

### Reference:

https://www.acqme.org/globalassets/pfassets/publicationspapers/pp\_gmeguide.pdf

Administered By:

Phillip D. Byrne, EdD

Phil By

Associate Dean of Graduate Medical Education